STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief

STAT PlusOpinionAdam’s Biotech Scorecard ‘No drama’ Diamantas should serve biotech well as acting FDA chief Plus: A look at how the industry fared on Wall Street during the Makary era Manage alerts for this article Email this article Share this article By Adam FeuersteinMay 14, 2026 Senior Writer, Biotech Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Kyle Diamantas, the acting commissioner of the Food and Drug Administration — newly installed following Marty Makary’s resignation — is expected to be a drama-free, stabilizing caretaker at the top of the agency.Advertisement Leadership turnover is always going to cause some angst, but based on what I’m hearing, biotech and the investors who track the sector have little to fear from Diamantas.

He is stepping into the new role after serving as the FDA’s top food regulator. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

You can reach Adam on Signal at stataf.54. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Adam's Biotech Scorecard May 7, 2026 STAT Plus: Color me skeptical: Drinking gold is not an ALS cure Adam's Biotech Scorecard April 30, 2026 STAT Plus: What does Akeso’s primo plenary spot say about its survival data? Advertisement Adam's Biotech Scorecard April 23, 2026 STAT Plus: Can Erasca be biotech’s next big thing?

We’ll see Adam's Biotech Scorecard April 16, 2026 STAT Plus: Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway Adam's Biotech Scorecard April 2, 2026 STAT Plus: ‘Takeover Tuesday’ saves biotech’s quarter Subscriber Picks